A Pharmacogenomic Promise
New testing can improve personalized treatment – but only with judicious validation and use
Michael Schubert | | Quick Read
Pharmacogenomic testing is an increasingly significant part of many laboratory medicine professionals’ work. The more we learn about genes that affect drug efficacy, metabolism, or even the likelihood of adverse events, the more we can test to ensure that each patient receives the appropriate dose of the appropriate drug with the appropriate monitoring. However, not all tests are equal; some have a greater evidence base behind them or may simply be easier for clinicians or patients to understand. As a result, the Association for Molecular Pathology (AMP) has developed a set of best practices for clinical pharmacogenomic testing. We spoke to Jordan Laser, Medical Director of Long Island Jewish Medical Center – Pathology and Laboratory Medicine and Chair of AMP’s Professional Relations Committee, to learn more.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.